Renal biomarkers in cats: A review of the current status in chronic kidney disease
Issued Date
2022-03-01
Resource Type
ISSN
08916640
eISSN
19391676
Scopus ID
2-s2.0-85125246364
Pubmed ID
35218249
Journal Title
Journal of Veterinary Internal Medicine
Volume
36
Issue
2
Start Page
379
End Page
396
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Veterinary Internal Medicine Vol.36 No.2 (2022) , 379-396
Suggested Citation
Kongtasai T., Paepe D., Meyer E., Mortier F., Marynissen S., Stammeleer L., Defauw P., Daminet S. Renal biomarkers in cats: A review of the current status in chronic kidney disease. Journal of Veterinary Internal Medicine Vol.36 No.2 (2022) , 379-396. 396. doi:10.1111/jvim.16377 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/87090
Title
Renal biomarkers in cats: A review of the current status in chronic kidney disease
Author's Affiliation
Other Contributor(s)
Abstract
Serum creatinine concentration, the classical biomarker of chronic kidney disease (CKD) in cats, has important limitations that decrease its value as a biomarker of early CKD. Recently, serum symmetric dimethylarginine concentration was introduced as a novel glomerular filtration rate biomarker for the early detection of CKD in cats. However, data on its specificity are still limited. The limitations of conventional biomarkers and the desire for early therapeutic intervention in cats with CKD to improve outcomes have prompted the discovery and validation of novel renal biomarkers to detect glomerular or tubular dysfunction. Changes in the serum or urinary concentrations of these biomarkers may indicate early kidney damage or predict the progression of kidney before changes in conventional biomarkers are detectable. This review summarizes current knowledge on renal biomarkers in CKD in cats, a field that has progressed substantially over the last 5 years.